0001178913-19-000046.txt : 20190103
0001178913-19-000046.hdr.sgml : 20190103
20190103160613
ACCESSION NUMBER: 0001178913-19-000046
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190101
FILED AS OF DATE: 20190103
DATE AS OF CHANGE: 20190103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harsch Mutya
CENTRAL INDEX KEY: 0001727809
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36621
FILM NUMBER: 19505393
MAIL ADDRESS:
STREET 1: C/O FOAMIX PHARMACEUTICALS LTD.
STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd.
CENTRAL INDEX KEY: 0001606645
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
BUSINESS PHONE: 97289316233
MAIL ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
FORMER COMPANY:
FORMER CONFORMED NAME: Foamix Ltd.
DATE OF NAME CHANGE: 20140428
4
1
zk1922433.xml
OWNERSHIP DOCUMENT
X0306
4
2019-01-01
0
0001606645
Foamix Pharmaceuticals Ltd.
FOMX
0001727809
Harsch Mutya
C/O FOAMIX PHARMACEUTICALS LTD.
2 HOLZMAN STREET
REHOVOT
L3
7670402
ISRAEL
0
1
0
0
CLO and General Counsel
Ordinary Shares
2019-01-01
4
A
0
30127
0.00
A
55127
D
Option (right to buy)
3.77
2019-01-01
4
A
0
70297
3.77
A
2029-01-01
Ordinary Shares
70297
70297
D
These shares are represented by restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the Issuer. The ordinary shares underlying this re-stricted share unit award vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereafter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date.
The ordinary shares underlying these options vest over a period of four years from the end of the calendar quarter in which the grant was made (25% on March 31, 2020, and 6.25% every three months thereafter on the last day of the quarter) ending March 31, 2023, subject to the reporting person's continuous service with the Issuer as of each such vesting date.
/s/ Mutya Harsch
2019-01-03